Current Bioequivalence Study Designs in South Korea: A Comprehensive Analysis of Bioequivalence Study Reports Between 2013 and 2019
Demonstration of bioequivalence (BE) is mandatory while developing generic drugs. The scientific concept of BE applies equally to different regulatory agencies. However, the application of the concept may differ for each agency, which can affect the design of BE studies. To evaluate the study practi...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-05-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.651790/full |
id |
doaj-e7d06d1f9b7e47019b476bab57a7d891 |
---|---|
record_format |
Article |
spelling |
doaj-e7d06d1f9b7e47019b476bab57a7d8912021-05-11T14:17:52ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-05-011210.3389/fphar.2021.651790651790Current Bioequivalence Study Designs in South Korea: A Comprehensive Analysis of Bioequivalence Study Reports Between 2013 and 2019Ki Young Huh0Eunwoo Kim1Soyoung Lee2Hyounggyoon Yoo3Seonghae Yoon4Kyung-Sang Yu5Jae-Yong Chung6Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South KoreaDepartment of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South KoreaDepartment of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South KoreaDepartment of Clinical Pharmacology and Therapeutics, CHA University Bundang Medical Center, CHA University School of Medicine, Gyeonggi-do, South KoreaDepartment of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Gyeonggi-do, South KoreaDepartment of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South KoreaDepartment of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Gyeonggi-do, South KoreaDemonstration of bioequivalence (BE) is mandatory while developing generic drugs. The scientific concept of BE applies equally to different regulatory agencies. However, the application of the concept may differ for each agency, which can affect the design of BE studies. To evaluate the study practices in terms of the BE concept in South Korea, we retrospectively analyzed BE study reports available from Ministry of Food and Drug Safety between 2013 and 2019. Statistical estimation of the pharmacokinetic parameters, including peak concentration and area under the concentration–time curve to the last measurable concentration, as well as study design, number of subjects in a study, study duration, fasting status, and formulation of specific drugs were obtained. The drugs were classified per World Health Organization Anatomical Therapeutic Chemical Classification and Biopharmaceutics Classification System. Post-hoc intrasubject coefficient of variation and corresponding sample sizes were calculated from the 90% confidence intervals of pharmacokinetic parameters. A total of 143 generic drugs in 588 BE studies were analyzed. The largest number of studies were performed in the area of Cardiovascular system (172 studies), followed by Nervous system (143 studies) and Alimentary tract and metabolism (92 studies). Overall, BE studies in South Korea were conducted in accordance with the global guideline despite the differences in details. BE studies were focused on the several therapeutic areas and conducted in a similar manner. The number of subjects was generally larger than that estimated with 90% power.https://www.frontiersin.org/articles/10.3389/fphar.2021.651790/fullbioequivalenceregulationsgeneric drugIntrasubject coefficient of variationbiopharmaceutics classification system |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ki Young Huh Eunwoo Kim Soyoung Lee Hyounggyoon Yoo Seonghae Yoon Kyung-Sang Yu Jae-Yong Chung |
spellingShingle |
Ki Young Huh Eunwoo Kim Soyoung Lee Hyounggyoon Yoo Seonghae Yoon Kyung-Sang Yu Jae-Yong Chung Current Bioequivalence Study Designs in South Korea: A Comprehensive Analysis of Bioequivalence Study Reports Between 2013 and 2019 Frontiers in Pharmacology bioequivalence regulations generic drug Intrasubject coefficient of variation biopharmaceutics classification system |
author_facet |
Ki Young Huh Eunwoo Kim Soyoung Lee Hyounggyoon Yoo Seonghae Yoon Kyung-Sang Yu Jae-Yong Chung |
author_sort |
Ki Young Huh |
title |
Current Bioequivalence Study Designs in South Korea: A Comprehensive Analysis of Bioequivalence Study Reports Between 2013 and 2019 |
title_short |
Current Bioequivalence Study Designs in South Korea: A Comprehensive Analysis of Bioequivalence Study Reports Between 2013 and 2019 |
title_full |
Current Bioequivalence Study Designs in South Korea: A Comprehensive Analysis of Bioequivalence Study Reports Between 2013 and 2019 |
title_fullStr |
Current Bioequivalence Study Designs in South Korea: A Comprehensive Analysis of Bioequivalence Study Reports Between 2013 and 2019 |
title_full_unstemmed |
Current Bioequivalence Study Designs in South Korea: A Comprehensive Analysis of Bioequivalence Study Reports Between 2013 and 2019 |
title_sort |
current bioequivalence study designs in south korea: a comprehensive analysis of bioequivalence study reports between 2013 and 2019 |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2021-05-01 |
description |
Demonstration of bioequivalence (BE) is mandatory while developing generic drugs. The scientific concept of BE applies equally to different regulatory agencies. However, the application of the concept may differ for each agency, which can affect the design of BE studies. To evaluate the study practices in terms of the BE concept in South Korea, we retrospectively analyzed BE study reports available from Ministry of Food and Drug Safety between 2013 and 2019. Statistical estimation of the pharmacokinetic parameters, including peak concentration and area under the concentration–time curve to the last measurable concentration, as well as study design, number of subjects in a study, study duration, fasting status, and formulation of specific drugs were obtained. The drugs were classified per World Health Organization Anatomical Therapeutic Chemical Classification and Biopharmaceutics Classification System. Post-hoc intrasubject coefficient of variation and corresponding sample sizes were calculated from the 90% confidence intervals of pharmacokinetic parameters. A total of 143 generic drugs in 588 BE studies were analyzed. The largest number of studies were performed in the area of Cardiovascular system (172 studies), followed by Nervous system (143 studies) and Alimentary tract and metabolism (92 studies). Overall, BE studies in South Korea were conducted in accordance with the global guideline despite the differences in details. BE studies were focused on the several therapeutic areas and conducted in a similar manner. The number of subjects was generally larger than that estimated with 90% power. |
topic |
bioequivalence regulations generic drug Intrasubject coefficient of variation biopharmaceutics classification system |
url |
https://www.frontiersin.org/articles/10.3389/fphar.2021.651790/full |
work_keys_str_mv |
AT kiyounghuh currentbioequivalencestudydesignsinsouthkoreaacomprehensiveanalysisofbioequivalencestudyreportsbetween2013and2019 AT eunwookim currentbioequivalencestudydesignsinsouthkoreaacomprehensiveanalysisofbioequivalencestudyreportsbetween2013and2019 AT soyounglee currentbioequivalencestudydesignsinsouthkoreaacomprehensiveanalysisofbioequivalencestudyreportsbetween2013and2019 AT hyounggyoonyoo currentbioequivalencestudydesignsinsouthkoreaacomprehensiveanalysisofbioequivalencestudyreportsbetween2013and2019 AT seonghaeyoon currentbioequivalencestudydesignsinsouthkoreaacomprehensiveanalysisofbioequivalencestudyreportsbetween2013and2019 AT kyungsangyu currentbioequivalencestudydesignsinsouthkoreaacomprehensiveanalysisofbioequivalencestudyreportsbetween2013and2019 AT jaeyongchung currentbioequivalencestudydesignsinsouthkoreaacomprehensiveanalysisofbioequivalencestudyreportsbetween2013and2019 |
_version_ |
1721444177351278592 |